Clinical research
ImmunityBio shared positive results from its clinical trial on its IL-15 superagonist Anktiva (N-803) to treat people living with human immunodeficiency virus (HIV).
Anavex Life Sciences announced positive topline results from its Phase III AVATAR trial of Anavex 2-73 (blarcamesione) in adult female patients with Rett syndrome.
Oak Hill Bio has a pipeline that includes two programs with Phase II proof-of-concept data in rare diseases with significant unmet needs.
Together, these two companies are combining their strengths to find treatment options for rare neuromuscular diseases.
You are what you eat, and your defense system notices that.
Altimmune announced Monday that the U.S. Food and Drug Administration (FDA) has approved a Phase II clinical trial for investigational new obesity drug pemvidutide.
The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.
WRNMC researchers have found a way to create a vaccine that can recognize multiple spike proteins at once by using ferritin. Here’s more about pan coronavirus vaccine.
News that a subvariant of the Omicron variant has appeared in the U.S. and parts of Europe doesn’t seem like good news. The latest data suggest it’s 1.5 times more transmissible than the original Omicron variant, but not necessarily deadlier.
Scientists believe that, perhaps, Alzheimer’s disease is a cause of not just beta-amyloid accumulation but, digging more deeply, immune system dysfunction.
PRESS RELEASES